Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
30 oct. 2024 08h30 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Global Liver Institute Welcomes Larry R. Holden as CEO
03 sept. 2024 09h54 HE
|
Global Liver Institute
Washington, DC, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Global Liver Institute (GLI), the premier liver patient advocacy organization, has appointed Larry R. Holden as the...
Renown Health pioneers HistoSonics Edison system delivering histotripsy for non-invasive liver tumor treatment
08 août 2024 16h18 HE
|
Renown Health
Reno, NEV., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Renown Health announced today that the first patients have received targeted liver tumor treatments through the Edison® System histotripsy technology,...
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
30 juil. 2024 02h00 HE
|
CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
29 juil. 2024 08h00 HE
|
CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
06 juin 2024 11h15 HE
|
Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
15 avr. 2024 08h05 HE
|
Organovo, Inc.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Conte
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
09 avr. 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network ...
[Latest] Global Liver Cancer Market Size/Share Worth USD 16.3 Billion by 2033 at a 14.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
03 avr. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, April 03, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Liver Cancer Market Size, Trends and Insights By Type (Hepatocellular Carcinoma...
For Rare Liver Disease Patients, Care Transitions Pose Yet Another Risk
01 févr. 2024 08h00 HE
|
Global Liver Institute
Washington, D.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Today marks the start of Global Liver Institute’s (GLI) 2024 #RareAware campaign, which calls attention to the more than 100 rare liver diseases...